About
Imbruvica (ibrutinib) is a pharmaceutical drug developed and marketed by AbbVie used to treat certain blood cancers including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and Waldenström's macroglobulinemia (WM).
Explore Imbruvica's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.